One of the things I want to caution you on in doing these international price comparisons is that every country has gone to an approach that makes it difficult to compare prices, if you will, directly. Every country is engaging in contracting in non-transparent negotiations. When you look at a price, it's no longer feasible in a reliable way to know what any country is paying for a particular drug, because manufacturers have adopted a model of negotiating non-transparent hidden discounts that they provide directly to governments.
The ability to use international prices as a way to assess the fairness of a price within an international context has diminished, if you will, so there are increasing questions about whether this continues to be an effective policy lever.